Pharmacologic Augmentation of Computerized Auditory Training in Chronic Psychosis: Preliminary Findings From a Single-Site, Double-Blind Study
Schizophrenia Bulletin · 2025
DOI: 10.1093/schbul/sbaf015 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Schizophrenia Bulletin, 2025. Verfasst von Neal R Swerdlow und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, UCSD School of Medicine, La Jolla, CA 92093, United States. Hauptthemen laut MEDLINE: Central Nervous System Stimulants, Cognitive Remediation, Dextroamphetamine, Dopamine Agents. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: RRD VA, NIMH NIH HHS, National Institute of Mental Health.
Abstract (Originalsprache)
Background
Computerized auditory training (AT) modestly improves symptoms, cognition, and functioning in schizophrenia. We assessed whether d-amphetamine (AMPH) or memantine (MEM) can enhance gains from 30-h of AT.
Methods
Antipsychotic-medicated individuals with chronic psychosis (n = 68; mean age 47.03y; M:F = 39:29) completed up to 30 AT sessions (2-3/week; n = 50 completed 30 sessions) in 3 groups: “AMPH group” (AMPH (5 mg po) 1-h before each AT session); “MEM group” (titrated to 10 mg MEM bid and maintained that dose throughout training); “PBO group” (PBO dosed identically to either AMPH or MEM). Primary (PANSS total, MCCB Composite, WHODAS) and secondary (PANSS positive, PANSS negative, YMRS, PHQ-9, PSYRATS) outcome measures were acquired at baseline, after 10, 20, and 30 AT sessions, and 12 weeks post-training. Pill identity (active/PBO) was blind to subjects and staff.
Results
Marginally significant between-group gains for AMPH vs PBO were detected for one of three primary outcomes (WHODAS, P =.050; but not PANSS total or MCCB Composite), and for 3 of 5 secondary clinical outcomes (PANSS positive, YMRS, PSYRATS, P’s≤.027–.049). Within-subject gains over time were detected for primary and secondary clinical measures for AMPH (P’s≤.014–.004) and MEM (P’s≤.02–.001) groups; some of these would not survive conservative correction for multiple comparisons. No measures detected symptom worsening; treatment satisfaction exceeded subjects’ expectations.
Conclusions
Results are mixed; drug-associated gains in several measures vs PBO suggest that these regimens may augment AT-induced functional and clinical improvement in psychosis patients, independent of changes in neurocognition. Assessment in larger samples seems warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, UCSD School of Medicine, La Jolla, CA 92093, United States.
- VISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, La Jolla, CA 92037, United States.
- Department of Psychology, Colorado State University, Fort Collins, CO 80523, United States.
ORCID-Profile: Joyce Sprock, Michael L Thomas
Förderung
- RRD VA
- NIMH NIH HHS
- National Institute of Mental Health
Zitieren
APA
Swerdlow, N. R., Sprock, J., Li, F., Din, J. M., Minhas, J., Talledo, J., Joshi, Y. B., Molina, J. L., Nordberg, B., Ing, K., Thomas, M. L., & Light, G. A. (2025). Pharmacologic Augmentation of Computerized Auditory Training in Chronic Psychosis: Preliminary Findings From a Single-Site, Double-Blind Study. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbaf015
Vancouver
Swerdlow NR, Sprock J, Li F, Din JM, Minhas J, Talledo J, et al. Pharmacologic Augmentation of Computerized Auditory Training in Chronic Psychosis: Preliminary Findings From a Single-Site, Double-Blind Study. Schizophrenia Bulletin. 2025. doi:10.1093/schbul/sbaf015
BibTeX
@article{Swerdlow2025,
author = {Swerdlow, Neal R and Sprock, Joyce and Li, Francesca and Din, Jenny Min and Minhas, Jessica and Talledo, Jo and Joshi, Yash B and Molina, Juan L and Nordberg, Bethany and Ing, Kevin and Thomas, Michael L and Light, Gregory A},
title = {Pharmacologic Augmentation of Computerized Auditory Training in Chronic Psychosis: Preliminary Findings From a Single-Site, Double-Blind Study},
journal = {Schizophrenia Bulletin},
year = {2025},
doi = {10.1093/schbul/sbaf015}
}
EUVIMED